NASDAQ: SRZN - Surrozen, Inc.

Rentabilität für sechs Monate: +41.17%
Dividendenrendite: 0.00%
Sektor: Healthcare

Aktionsplan Surrozen, Inc.

Erweiterter Zeitplan Einfaches Diagramm
Financial Markets by TradingView

Über das Unternehmen Surrozen, Inc.

Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. The company is developing antibody-based therapeutics with application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system.

weitere details
Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcoholic hepatitis and asialoglycoprotein receptor 1; and SZN-1326, a bi-specific antibody, which is in Phase 1b clinical trial for the treatment of moderate to severe inflammatory bowel disease, Frizzled, and LRP receptors. The company also develops SZN-413, a Fzd4 targeted bi-specific antibody, which is in preclinical stage for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. was founded in 2015 and is based in South San Francisco, California.
Zur Vergleichsliste hinzufügen
Auf die Beobachtungsliste
Zum Portfolio hinzufügen
Preishinweis hinzufügen

IPO date 2021-01-11
ISIN US86889P1093
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.surrozen.com
Цена ао 11.89
Preisänderung pro Tag: 0% (11.59)
Preisänderung pro Woche: -1.02% (11.71)
Preisänderung pro Monat: +8.32% (10.7)
Preisänderung über 3 Monate: +15.9% (10)
Preisänderung über sechs Monate: +41.17% (8.21)
Preisänderung pro Jahr: -13.02% (13.325)
Preisänderung über 3 Jahre: +219.28% (3.63)
Preisänderung seit Jahresbeginn: +9.7% (10.565)
Alle Parameter

Unterschätzung

Name Bedeutung Grad
P/S 1.35 9
P/BV 0.4458 10
P/E 0 0
EV/EBITDA 0.3831 10
Gesamt: 6.13

Effizienz

Name Bedeutung Grad
ROA, % -93.41 0
ROE, % -113.46 0
Gesamt: 0

Dividenden

Name Bedeutung Grad
Div yield, % 0 0
DSI 0 0
Gesamt: 0

Pflicht

Name Bedeutung Grad
Debt/EBITDA -0.0822 10
Gesamt: 9.8

Wachstumsimpuls

Name Bedeutung Grad
Rentabilität Revenue, % 0 0
Rentabilität Ebitda, % 80.4 9
Rentabilität EPS, % 416.44 10
Gesamt: 7.2
Weitere Details

Institutionen Volumen Aktie, %
Column Group LLC 627651 19.62
Euclidean Capital LLC 87696 2.74
Blackrock Inc. 58494 1.83
ArrowMark Colorado Holdings LLC 55123 1.72
Board Of Trustees Of The Leland Stanford Junior University 52131 1.63
Trustees Of Columbia University In The City Of New York 47930 1.5
Morgan Stanley 35211 1.1
Vanguard Group Inc 32511 1.02
Alyeska Investment Group, L.P. 20376 0.64
Geode Capital Management, LLC 11473 0.36

ETFAktie, %Rentabilität für das Jahr, %Dividenden, %
iShares Micro-Cap ETF 0.00519 17.09 1.54048
0.0117.091.54



Aufsicht Berufsbezeichnung Zahlung Geburtsjahr
Mr. Craig C. Parker M.B.A. CEO, President & Director 825.32k 1962 (63 Jahr)
Mr. Charles Williams CFO, COO & Corporate Secretary 611.03k 1980 (45 Jahre)
Dr. K. Christopher Garcia Ph.D. Co-Founder & Member of Scientific Advisory Board N/A
Dr. Roeland Nusse Ph.D. Co-Founder & Member of Scientific Advisory Board N/A 1950 (75 Jahre)
Dr. Calvin Kuo M.D., Ph.D. Co-Founder & Member of Scientific Advisor N/A
Dr. Li Yang Ph.D. Executive Vice President of Research 535.46k 1969 (56 Jahre)
Esther Jhun Controller N/A

Adresse: United States, South San Francisco. CA, 171 Oyster Point Boulevard - in Google Maps öffnen, Öffnen Sie Yandex-Karten
Webseite: https://www.surrozen.com